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INTRODUCTION
Cervical cancer is one of the most common causes of cancer 
death among women worldwide, despite implementation of 
the Papanicolaou (Pap) smear test, which has dramatically de-
creased the incidence of cervical cancer in developed nations 
over the past 30 years [1]. Cervical cancer incidence and mor-
tality have been decreasing continuously in Korea. However, 
cervical cancer remains a clinically important disease; in fact, 
it is the sixth most common cancer among women and first 
among female genital malignancies. Thus, it is a major health 
problem for Korean women. Indeed, in 2008, an estimated 
3,888 new cases were diagnosed, accounting for 4.5% of new 
female cancer cases. The incidence rate per 100,000 women 
was 11.2 in 2008, down from a high of 16.3 in 1999. Survival 
rates have also improved [2].
Since population-based cervical cancer screening was intro-
duced, cervical cancer screening, including opportunistic as 
well as organized screening, has been widely available [3,4]. 
Currently, two population-based organized cancer screen-
ing programs exist in Korea: the National Cancer Screening 
Program (NCSP), whose target population includes Medical 
Aid Program (MAP) recipients and the lower 50% of National 
Health Insurance (NHI) beneficiaries, and the NHI Cancer 
Screening Program (NHICSP), which is provided to the up-
per 50% of NHI beneficiaries by NHI Corporation. These two 
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Objective: The National Cancer Screening Program (NCSP) began in 1999. In this report, we evaluate the results of the NCSP for 
cervical cancer in 2009 and provide participation rates in an organized cervical cancer screening program in Korea.
Methods: Using data obtained from the National Cancer Screening Information System, cervical cancer screening participation 
rates were calculated. Recall rates, defined as the proportion of abnormal cases among women screened, were also estimated 
with 95% confidence intervals.
Results: The target population of cervical cancer screening in 2009 included 4,577,200 Korean women aged 30 and over, 
1,349,668 of whom underwent the Papanicolaou smear test (29.5% participation rate). Compared with the participation rate of 
women covered by the National Health Insurance Program (31.3%), the participation rate of women covered by the Medical Aid 
Program was lower (18.4%). Participation rates also varied in different age groups (the highest of 39.3% in women aged 50 to 59 
and the lowest of 14.4% in those aged 70 and older), and different areas (the highest of 34.1% in Busan and the lowest of 21.5% 
in Chungnam). The overall recall rate for cervical cancer screening was 0.41% (95% confidence interval, 0.40 to 0.42).
Conclusion: According to our study, efforts to facilitate participation and reduce disparities in cervical cancer screening among 
Korean women are needed.
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programs provide a screening test free of charge to all Korean 
women aged 30 and over, biennially [5].
In the present study, we sought to provide preliminary infor-
mation on the NCSP for cervical cancer, based on data collected 
in 2009. This report describes participation rates and the per-
centage of abnormalities by age and insurance type. Results 
for the NHICSP will be reported by the NHI Corporation.
MATERIALS AND METHODS
1. Study population
In this study, we utilized the database of the 2009 NCSP for 
cervical cancer. Korean women are instructed to be screened 
biennially, and the standard modality for cervical cancer scree-
ning is the Pap smear test. The target population for cervical 
cancer screening in the 2009 NCSP consisted of 4,577,200 wo-
men born in 1979 or earlier (i.e., aged 30 years and older, with 
a mean age of 51.9±11.0 years) who were MAP recipients or 
NHI beneficiaries in the lower 50% of the income bracket. For 
those NHI beneficiaries who were included in the NCSP, the 
in  surance premium was US$ 60 (1 USD=1,000 KWR) or less 
per month for employees and US$ 72 or less per month for 
the self-employed (based on November, 2008). 
Participation in the NCSP was confirmed based on claims 
and cervical cancer screening results submitted to the NHI 
Corporation before December 31, 2009. All screening was 
done between January 1, 2009, and December 31, 2009. Some 
subjects underwent the same screening procedure multiple 
times; for those individuals, only the first screen was counted 
(n=11,465). These participants were only counted once in de-
termining the participation rate.
2. Variables
The NCSP for cervical cancer reported Pap test results by 
using the 2001 Bethesda System categories [6]. The screen-
ing results were assigned to one of the following categories: 
normal, infection/reaction, atypical squamous cells of unde-
termined significance (ASCUS), low-grade squamous intraepi-
thelial lesion (LSIL), high-grade squamous intraepithelial lesion 
(HSIL), squamous cell carcinoma, and “other”. The category 
“other” included Pap smear results relating only to glandular 
elements of the genital tract and hormonal evaluations. Pap 
smear results were defined as abnormal if they were reported 
as LSIL, HSIL, adenocarcinoma in situ (AIS), or squamous or ad-
enomatous cell carcinoma [7].
3. Statistical analysis
The participation rate of cervical cancer screening was cal-
culated by dividing the number of participants by the target 
population of the NCSP for cervical cancer, and is denoted as 
a percentage. Recall rates for cervical cancer screening were 
defined as the proportion of abnormal cases among the can-
cer-screened participants; 95% confidence intervals (CIs) were 
calculated for all recall rates. SAS ver. 9.1 (SAS Institute, Cary, 
NC, USA) was used in all statistical analyses.
RESULTS
Table 1 shows the screening outcomes by age, health insur-
ance type, and area of residence. The target population of the 
2009 NCSP for cervical cancer screening included 4,577,200 
females; among them, 1,349,668 underwent the Pap smear 
test, giving a participation rate of 29.5%. In terms of age, the 
participation rate was highest (39.3%) among females aged 
50 to 59 years and the lowest (14.4%) among those aged 70 
years and older. Regionnally, while the participation rate was 
the highest (34.1%) in Busan, which is the second largest city 
in Korea, it was the lowest (21.5%) in Chungnam, which is a 
rural area. 
Recall rates in women aged 70 years and older and in their 
30s, in contrast to the participation rates, were higher than 
those in the other age groups. Among the age groups, the 
range of recall rates for women in the NHI program was 0.31-
0.51%; however, for those who were MAP recipients, the range 
was 0.30-0.68%, making the recall rate of women aged 70 
years and older and in their 30s twice that of women in their 
50s. Except for women in their 50s, in each age group the re-
call rate for women who were MAP recipients was higher than 
that for women who were NHI beneficiaries (Table 1).
The number of participants among NHI beneficiaries de-
creased with age, whereas the number of participants who 
were MAP recipients did not change with age (Fig. 1). The 
overall participation rate of NHI beneficiaries was higher than 
that of MAP recipients (31.3 and 18.4%, respectively). Addi-
tionally, the participation rate of NHI beneficiaries compared 
with MAP recipients was higher for all age groups (Fig. 2). The 
participation rates in women aged 70 years and older and in 
their 30s were lower than those for the other age groups. The 
same was true for women who were NHI beneficiaries and 
MAP recipients. Women who were MAP recipients were esti-
mated to have lower participation rates than those in the NHI 
group for each age group.
Of all participants, 0.41% (5,529) represented abnormal cases. 
Compared with health insurance beneficiaries, the rate of ab-
normal cases involving MAP recipients was higher than those 
involving NHI beneficiaries by 0.12%. Regarding age, the ab-Young Hwa Lee, et al.
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Table 1. Screening outcomes by age, health insurance type, and area of residence from the National Cancer Screening Program for cervical can  cer, 2009
　 Target population Participants Participation rate (%) Abnormal cases*  Recall rate (%) (95% CI)
Total 4,577,200  1,349,668  29.5 5,529  0.41 (0.40-0.42)
Health insurance type
  NHI 3,937,299  1,231,853  31.3 4,921  0.40 (0.39-0.41)
  MAP 639,901  117,815  18.4 608  0.52 (0.48-0.56)
Age group (yr) 　 　 　 　
  30-39 772,454  138,603  17.9 668  0.48 (0.45-0.52)
  40-49 1,378,692  439,891  31.9 2,044  0.46 (0.44-0.48)
  50-59 1,101,955  432,526  39.3 1,466  0.34 (0.32-0.36)
  60-69 625,209  237,888  38.1 787  0.33 (0.31-0.35)
  ≥70 698,890  100,760  14.4 564  0.56 (0.51-0.61)
Area of residence 　 　 　
  Seoul 842,322  257,575  30.6 1,086  0.42 (0.40-0.45)
  Busan 358,448  122,342  34.1 585  0.48 (0.44-0.52)
  Daegu 238,706  75,026  31.4 265  0.35 (0.31-0.40)
  Daejeon 125,482  42,785  34.1 160  0.37 (0.32-0.43)
  Incheon 250,143  69,747  27.9 361  0.52 (0.46-0.57)
  Gwangju 126,333  42,041  33.3 135  0.32 (0.27-0.38)
  Ulsan 77,877  23,780  30.5 84  0.35 (0.28-0.43)
  Gyeonggi 945,817  279,948  29.6 1,350  0.48 (0.46-0.51)
  Gangwon 159,157  44,845  28.2 158  0.35 (0.30-0.41)
  Chungbuk 159,623  46,622  29.2 126  0.27 (0.22-0.32)
  Chungnam 208,691  44,826  21.5 185  0.41 (0.35-0.47)
  Jeolbuk 203,909  57,574  28.2 223  0.39 (0.34-0.44)
  Jeolnam 221,441  59,059  26.7 220  0.37 (0.32-0.42)
  Gyeongbuk 287,807  76,549  26.6 286  0.37 (0.33-0.42)
  Gyeongnam 313,546  90,888  29.0 246  0.27 (0.24-0.30)
  Jeju 57,898  16,061  27.7 59  0.37 (0.27-0.46)
CI, confidence interval; NHI, National Health Insurance; MAP, Medical Aid Program.
*Includes low-grade intraepithelial lesions, high-grade intraepithelial lesions, adenocarcinoma in situ, and squamous or adenomatous cell 
cancer.
Fig. 1. Number of participants by health insurance type and age from 
the National Cancer Screening Program for cervical cancer, 2009.
Fig. 2. Participation rates by health insurance type and age from the 
National Cancer Screening Program for cervical cancer, 2009.Cervical cancer screening in Korea, 2009
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normal rate decreased for older women but increased sharply 
for women aged 70 years and older (Table 2). The U-shaped 
curve representing abnormal tests by age diverged from 
0.48% for women in their 30s, reached a minimum (0.33%) for 
women in their 60s, and approached 0.56% for women aged 
70 years and older (Fig. 3). With increasing age, the proportion 
of LSILs reported decreased, while the proportions of HSILs 
and squamous cell carcinoma increased.
DISCUSSION
The participation rate in the 2009 NCSP for cervical cancer 
was 29.5%. Participation rates have tended to increase since 
the first participation rate for cervical cancer screening in the 
NCSP was estimated at 15.4% in 2002 [5]. However, the rate 
remains at a lower level compared with those in countries 
that have established screening programs, although it is high-
er than that in Japan which is also located in Asia. Regarding 
Europe, fourteen countries operate cervical cancer prevention 
programs, and their participation rates reportedly range from 
10 to 79% [8]. Northern European countries that launched a 
similar program in the 1960s, including Finland, Sweden, and 
Denmark, report participation rates in excess of 75% [9]. The 
US has a National Breast and Cervical Cancer Early Detection 
Program (NBCCEDP), which was adopted in 1991 and which 
provides low-income, uninsured, and minority women with 
screening and diagnostic services for breast and cervical 
cancer; that program’s participation rate for cervical cancer 
screening is 78.3% [10-12]. In 1998, the UK implemented the 
NHS Cancer Screening Program for women. In that country, 
the Pap smear test had been used to detect cervical cancer, 
but the liquid-based cytology method replaced it in 2003. 
The participation rate for cervical cancer screening in the UK 
was 78.9% as of March, 2009 [13]. In Japan, local governments 
instituted a cancer detection program in the 1960s; however, 
this was replaced by a national cancer detection program 
run by the central government upon establishment of the 
Health and Medical Services Law for the Aged. Cervical can-
cer screening started in 1982, and the participation rate was 
18.8% in 2009 [14,15].
For early cancer detection programs, the participation rate is 
very important because early adoption of detection programs 
Table 2. Distribution of Papanicolaou smear test results by age group and health insurance type in the National Cancer Screening Program for 
cervical cancer, 2009
Results All*         
(n=1,208,581)
Health insurance type Age (yr)
NHI
(n=1,231,853)
MAP
(n=117,815)
30-39
 (n=138,603) 
40-49
 (n=439,889) 
50-59
 (n=432,517) 
60-69
 (n=237,888) 
70+
 (n=100,760) 
Normal 950,068 (70.4) 866,119 (70.3) 83,949 (71.3) 96,312 (69.5) 303,034 (68.9) 303,602 (70.2) 172,792 (72.6) 74,328 (73.8)
Epithelial cell abnormality 22,631 (1.7) 20,385 (1.7) 2,246 (1.9) 2,584 (1.9) 8,245 (1.9) 6,680 (1.5) 3,310 (1.4) 1,812 (1.8)
   Squamous cell 20,684 　 18,628 2,056 2,388 　 7,575 　 6,087 　 2,983 　 1,651 　
   Glandular cell 456 　 408 48 59 　 189 　 133 　 47 　 28 　
   Unknown 1,491 　 1,349 142 137 　 481 　 460 　 280 　 133 　
Negative for intraepithelial
  lesion or malignancy
366,664 (27.2) 335,969 (27.3) 30,695 (26.1) 39,216 (28.3) 126,587 (28.8) 118,532 (27.4) 58,923 (24.8) 23,406 (23.2)
   Organisms 110,473 　 101,819 8,654 11,684 　 40,107 　 36,667 　 16,255 　 5,760 　
   Reactive cellular changes 256,191 　 234,150 22,041 27,532 　 86,480 　 81,865 　 42,668 　 17,646 　
Other 10,294 (0.8) 9,369 (0.8) 925 (0.8) 491 (0.4) 2,023 (0.5) 3,703 (0.9) 2,863 (1.2) 1,214 (1.2)
Total abnormal
† 5,529 (0.41) 4,921 (0.40) 608 (0.52) 668 (0.48) 2,044 (0.46) 1,466 (0.34) 787 (0.33) 564 (0.56)
Values are presented as number (%).
MAP, Medical Aid Program; NHI, National Health Insurance.
*Individuals without available screening results were excluded (n=11). 
†Includes low-grade intraepithelial lesions, high-grade intraepithelial 
lesions, adenocarcinoma in situ, and squamous or adenomatous cell cancer.
Fig. 3. Proportion of abnormal results by age from the National 
Cancer Screening Program for cervical cancer, 2009. LSIL, low-grade 
intraepithelial lesions; HSIL, high-grade intraepithelial lesions; SCC, 
squamous cell cancer.Young Hwa Lee, et al.
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effectively lowers the incidence and mortality rate of cervical 
cancer, and the incidence rate decreases as an individual re-
peats the test [16]. In Sweden, which launched its cervical can-
cer early detection program in 1958, the number of patients 
in the terminal stage was dramatically reduced, making care 
for cancer patients more efficient [17]. In the US, women aged 
18 years and over participate in cervical cancer screening tests 
every 3 years using the Pap smear test, and the incidence 
rate continues to decrease [10]. In Korea, a steady decline in 
both the incidence and mortality of cervical cancer has been 
observed; the incidence of cervical cancer decreased by 4.6% 
annually from 1999 to 2008 [2,18].
The NCSP for cervical cancer has shown a decreased inci-
dence rate of cervical cancer and has had a positive effect on 
cancer management; however, several problems remain to 
be addressed. First, although the cervical cancer screening 
program is free of charge to participants, the participation rate 
among MAP recipients was 18.4%, which is much lower than 
that among NHI beneficiaries (31.3%). Moreover, the recall 
rate of MAP recipients was 0.52%, which is higher than that of 
NHI beneficiaries (0.40%). Regarding the US, as socioeconomic 
status is lowered, the incidence rate increases [19], and as the 
cumulative number of participants undergoing screening in-
creases, the prevalence rate decreases [10]. In Korea, sociode-
mographic factors such as being married, having a higher ed-
ucation, a rural residence, and private health insurance were 
significantly associated with higher participation rates of cer-
vical cancer screening. However, household income was not a 
significant factor. Additionally, the perception of not needing 
a Pap test due to good health or an absence of symptoms was 
the most frequently reported barrier to participation in cervi-
cal cancer screening [20]. Thus, stronger efforts are required 
to identify what obstructs MAP recipients from participating 
in the detection program and to develop proper institutional 
measures. 
Second, regarding age, the participation and recall rates of 
women in their 30s were 17.9 and 0.48%, respectively. This 
represents the lowest and highest rates, respectively, except 
for women aged 70 years and older. Considering that the in-
cidence rate among younger women is rising while the over-
all incidence rate is falling [21,22], women in their 30s must 
participate in a screening program to prevent cervical cancer. 
Additionally, the participation and recall rates of women aged 
70 years and older were relatively low and high, respectively. 
Elderly women are said to be vulnerable to cervical cancer be-
cause they believe that menopause frees them from diseases 
involving the reproductive organs; thus, they tend not to par-
ticipate in prevention programs. The US once limited the age 
of eligibility for the Pap smear test to 65 years; however, in a 
consensus statement announced at the National Institutes 
of Health Consensus Development Conference Statement 
on Cervical Cancer, women aged 65 and older were encour-
aged to continuously attend the screening program [23]. This 
implies that constant care for cervical cancer is needed after 
menopause, and the extension of average lifespan calls for 
extending the prevention period. 
Differences in participation rates were identified according 
to health insurance type, age, and area of residence. Hence, 
along with improving the participation rate for cervical cancer 
screening, continuing efforts are required to minimize these 
differences. We expect that our results will be useful in creat-
ing policies and new studies to improve efforts to prevent 
cervical cancer in Korea.
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